Bio-Techne Corporation (TECH)
USD 48.81
(-6.69%)
USD 48.81
(-6.69%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 326.66 Million USD | -32.61% |
| 2023 | 460.56 Million USD | 2.14% |
| 2022 | 420.11 Million USD | 67.58% |
| 2021 | 258.47 Million USD | 50.74% |
| 2020 | 373.9 Million USD | 7.29% |
| 2019 | 211.89 Million USD | 7.74% |
| 2018 | 200.6 Million USD | 11.82% |
| 2017 | 179.35 Million USD | -19.13% |
| 2016 | 191.99 Million USD | 2.43% |
| 2015 | 192.93 Million USD | -7.97% |
| 2014 | 180.56 Million USD | -5.06% |
| 2013 | 172.98 Million USD | -7.12% |
| 2012 | 174.66 Million USD | 4.37% |
| 2011 | 173.68 Million USD | 7.45% |
| 2010 | 164.57 Million USD | -2.79% |
| 2009 | 158.54 Million USD | 7.78% |
| 2008 | 151.54 Million USD | 15.31% |
| 2007 | 137 Million USD | 14.74% |
| 2006 | 115.45 Million USD | 10.96% |
| 2005 | 103.87 Million USD | 15.91% |
| 2004 | 88.31 Million USD | 22.14% |
| 2003 | 74.07 Million USD | -10.62% |
| 2002 | 65.5 Million USD | 41.79% |
| 2001 | 58.54 Million USD | 12.59% |
| 2000 | 51.99 Million USD | 44.03% |
| 1999 | 37 Million USD | 61.88% |
| 1998 | 23.5 Million USD | 31.95% |
| 1997 | 17.6 Million USD | 23.36% |
| 1996 | 14.1 Million USD | 25.69% |
| 1995 | 11.1 Million USD | 11.22% |
| 1994 | 9.4 Million USD | 13.95% |
| 1993 | 8.2 Million USD | 48.28% |
| 1992 | 5.1 Million USD | 123.08% |
| 1991 | 2.7 Million USD | 50.0% |
| 1990 | 1.8 Million USD | 125.0% |
| 1989 | 800 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 65.51 Million USD | -7.31% |
| 2024 Q1 | 84.4 Million USD | -23.83% |
| 2024 Q3 | 99.29 Million USD | 27.45% |
| 2024 Q4 | 107.04 Million USD | -2.59% |
| 2024 FY | - USD | -10.2% |
| 2023 FY | - USD | 2.14% |
| 2023 Q1 | 82.95 Million USD | -22.06% |
| 2023 Q2 | 94.59 Million USD | 14.03% |
| 2023 Q4 | 121.44 Million USD | 13.31% |
| 2023 Q3 | 107.18 Million USD | 13.31% |
| 2022 Q3 | 115.81 Million USD | 32.43% |
| 2022 Q4 | 106.43 Million USD | -8.09% |
| 2022 FY | - USD | 67.58% |
| 2022 Q2 | 87.45 Million USD | -0.58% |
| 2022 Q1 | 87.95 Million USD | 28.25% |
| 2021 Q3 | 68.62 Million USD | 34.57% |
| 2021 Q4 | 68.58 Million USD | -0.06% |
| 2021 Q1 | 49.09 Million USD | 24.88% |
| 2021 Q2 | 50.99 Million USD | 3.88% |
| 2021 FY | - USD | 50.74% |
| 2020 Q4 | 39.31 Million USD | -17.74% |
| 2020 Q1 | 33.32 Million USD | -22.97% |
| 2020 Q2 | 36.99 Million USD | 11.0% |
| 2020 Q3 | 47.79 Million USD | 29.19% |
| 2020 FY | - USD | 7.29% |
| 2019 FY | - USD | 7.74% |
| 2019 Q1 | 25.76 Million USD | -39.97% |
| 2019 Q4 | 43.26 Million USD | -1.88% |
| 2019 Q3 | 44.09 Million USD | 31.21% |
| 2019 Q2 | 33.6 Million USD | 30.43% |
| 2018 Q1 | 26.03 Million USD | -37.24% |
| 2018 FY | - USD | 11.82% |
| 2018 Q4 | 42.91 Million USD | -0.39% |
| 2018 Q3 | 43.08 Million USD | 78.42% |
| 2018 Q2 | 24.14 Million USD | -7.23% |
| 2017 Q2 | 16.14 Million USD | -36.54% |
| 2017 Q3 | 32.3 Million USD | 100.08% |
| 2017 Q1 | 25.44 Million USD | -36.41% |
| 2017 FY | - USD | -19.13% |
| 2017 Q4 | 41.47 Million USD | 28.39% |
| 2016 Q1 | 31.02 Million USD | -17.91% |
| 2016 FY | - USD | 2.43% |
| 2016 Q2 | 36.02 Million USD | 16.1% |
| 2016 Q4 | 40.01 Million USD | -8.08% |
| 2016 Q3 | 43.52 Million USD | 20.82% |
| 2015 Q3 | 39.42 Million USD | 14.01% |
| 2015 FY | - USD | -7.97% |
| 2015 Q4 | 37.8 Million USD | -4.12% |
| 2015 Q2 | 34.58 Million USD | -1.81% |
| 2015 Q1 | 35.21 Million USD | -9.34% |
| 2014 Q1 | 43.43 Million USD | 6.74% |
| 2014 Q2 | 40.56 Million USD | -6.59% |
| 2014 FY | - USD | -5.06% |
| 2014 Q4 | 38.84 Million USD | -15.13% |
| 2014 Q3 | 45.76 Million USD | 12.83% |
| 2013 FY | - USD | -7.12% |
| 2013 Q4 | 40.68 Million USD | -12.8% |
| 2013 Q3 | 46.65 Million USD | 16.86% |
| 2013 Q2 | 39.92 Million USD | -2.58% |
| 2013 Q1 | 40.98 Million USD | -1.0% |
| 2012 Q1 | 45.25 Million USD | -1.21% |
| 2012 Q3 | 53.04 Million USD | 27.91% |
| 2012 Q2 | 41.46 Million USD | -8.37% |
| 2012 Q4 | 41.39 Million USD | -21.95% |
| 2012 FY | - USD | 4.37% |
| 2011 Q4 | 45.81 Million USD | -2.62% |
| 2011 FY | - USD | 7.45% |
| 2011 Q1 | 38.79 Million USD | -8.35% |
| 2011 Q2 | 38.22 Million USD | -1.47% |
| 2011 Q3 | 47.04 Million USD | 23.08% |
| 2010 Q1 | 41.86 Million USD | -2.7% |
| 2010 FY | - USD | -2.79% |
| 2010 Q4 | 42.32 Million USD | -1.89% |
| 2010 Q3 | 43.13 Million USD | 8.86% |
| 2010 Q2 | 39.62 Million USD | -5.36% |
| 2009 Q2 | 34.48 Million USD | -21.27% |
| 2009 Q3 | 43.46 Million USD | 26.05% |
| 2009 Q4 | 43.03 Million USD | -1.01% |
| 2009 FY | - USD | 7.78% |
| 2009 Q1 | 43.8 Million USD | 4.58% |
| 2008 FY | - USD | 15.31% |
| 2008 Q3 | 42.55 Million USD | 23.96% |
| 2008 Q1 | 34.04 Million USD | -3.31% |
| 2008 Q2 | 34.32 Million USD | 0.85% |
| 2008 Q4 | 41.88 Million USD | -1.57% |
| 2007 Q4 | 35.2 Million USD | -7.13% |
| 2007 FY | - USD | 14.74% |
| 2007 Q3 | 37.91 Million USD | 30.2% |
| 2007 Q2 | 29.11 Million USD | -4.31% |
| 2007 Q1 | 30.42 Million USD | -1.4% |
| 2006 Q2 | 26.29 Million USD | -2.19% |
| 2006 Q1 | 26.88 Million USD | -5.0% |
| 2006 FY | - USD | 10.96% |
| 2006 Q4 | 30.86 Million USD | -5.05% |
| 2006 Q3 | 32.5 Million USD | 23.6% |
| 2005 Q1 | 23.39 Million USD | -8.52% |
| 2005 FY | - USD | 15.91% |
| 2005 Q2 | 24.03 Million USD | 2.74% |
| 2005 Q4 | 28.3 Million USD | -3.45% |
| 2005 Q3 | 29.31 Million USD | 21.97% |
| 2004 Q1 | 20.45 Million USD | -1.13% |
| 2004 Q3 | 24.6 Million USD | 23.09% |
| 2004 Q4 | 25.56 Million USD | 3.91% |
| 2004 Q2 | 19.98 Million USD | -2.28% |
| 2004 FY | - USD | 22.14% |
| 2003 Q4 | 20.64 Million USD | 3.03% |
| 2003 Q3 | 20.14 Million USD | 24.54% |
| 2003 FY | - USD | -10.62% |
| 2003 Q1 | 16.99 Million USD | -4.62% |
| 2003 Q2 | 16.14 Million USD | -5.14% |
| 2002 FY | - USD | 41.79% |
| 2002 Q1 | 14.75 Million USD | -8.27% |
| 2002 Q2 | 14.96 Million USD | 1.42% |
| 2002 Q3 | 17.95 Million USD | 19.96% |
| 2002 Q4 | 17.82 Million USD | -0.77% |
| 2001 FY | - USD | 12.59% |
| 2001 Q4 | 16.08 Million USD | -8.06% |
| 2001 Q3 | 17.49 Million USD | 33.55% |
| 2001 Q2 | 13.1 Million USD | -6.88% |
| 2001 Q1 | 14.07 Million USD | -7.83% |
| 2000 Q3 | 14.45 Million USD | 26.76% |
| 2000 Q1 | 10.8 Million USD | 2.86% |
| 2000 Q2 | 11.4 Million USD | 5.56% |
| 2000 FY | - USD | 44.03% |
| 2000 Q4 | 15.26 Million USD | 5.65% |
| 1999 Q4 | 10.7 Million USD | 9.38% |
| 1999 Q3 | 9.8 Million USD | 15.66% |
| 1999 FY | - USD | 61.88% |
| 1999 Q2 | 8.5 Million USD | 6.41% |
| 1999 Q1 | 8 Million USD | 11.43% |
| 1998 Q4 | 7.4 Million USD | 14.75% |
| 1998 Q3 | 6.4 Million USD | 38.64% |
| 1998 Q2 | 4.7 Million USD | -10.2% |
| 1998 Q1 | 5.1 Million USD | -9.26% |
| 1998 FY | - USD | 31.95% |
| 1997 Q1 | 3.5 Million USD | -20.93% |
| 1997 FY | - USD | 23.36% |
| 1997 Q2 | 3.8 Million USD | 8.82% |
| 1997 Q3 | 4.8 Million USD | 24.32% |
| 1997 Q4 | 5.6 Million USD | 17.39% |
| 1996 FY | - USD | 25.69% |
| 1996 Q4 | 4.4 Million USD | 2.38% |
| 1996 Q3 | 4.1 Million USD | 75.0% |
| 1996 Q1 | 2.9 Million USD | -12.5% |
| 1996 Q2 | 2.6 Million USD | -14.29% |
| 1995 Q1 | 2.5 Million USD | -16.67% |
| 1995 Q2 | 2.4 Million USD | -4.0% |
| 1995 Q3 | 3 Million USD | 20.83% |
| 1995 Q4 | 3.3 Million USD | 10.34% |
| 1995 FY | - USD | 11.22% |
| 1994 Q1 | 2 Million USD | -17.39% |
| 1994 FY | - USD | 13.95% |
| 1994 Q3 | 2.6 Million USD | 47.37% |
| 1994 Q4 | 2.9 Million USD | 7.14% |
| 1994 Q2 | 1.8 Million USD | 0.0% |
| 1993 FY | - USD | 48.28% |
| 1993 Q1 | 1.8 Million USD | -34.48% |
| 1993 Q2 | 1.8 Million USD | -5.26% |
| 1993 Q3 | 2.3 Million USD | 33.33% |
| 1993 Q4 | 2.2 Million USD | -4.17% |
| 1992 Q4 | 2.4 Million USD | 93.33% |
| 1992 Q3 | 1.5 Million USD | 50.0% |
| 1992 Q2 | 1 Million USD | 25.0% |
| 1992 FY | - USD | 123.08% |
| 1992 Q1 | 500 Thousand USD | -20.0% |
| 1991 Q2 | 500 Thousand USD | 0.0% |
| 1991 Q4 | 1 Million USD | 25.0% |
| 1991 Q1 | 500 Thousand USD | -37.5% |
| 1991 Q3 | 800 Thousand USD | 60.0% |
| 1991 FY | - USD | 52.94% |
| 1990 FY | - USD | 142.86% |
| 1990 Q4 | 800 Thousand USD | 60.0% |
| 1990 Q2 | 200 Thousand USD | -33.33% |
| 1990 Q3 | 500 Thousand USD | 150.0% |
| 1990 Q1 | 300 Thousand USD | 0.0% |
| 1989 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -6.86 Million USD | 4856.305% |
| Jaguar Health, Inc. | -33.13 Million USD | 1085.974% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 314.66% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 675.577% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 226.495% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -221.117% |
| ContextLogic Inc. | -324 Million USD | 200.822% |
| MiMedx Group, Inc. | 40.51 Million USD | -706.237% |
| MEI Pharma, Inc. | 26.38 Million USD | -1138.298% |
| AlloVir, Inc. | -190.14 Million USD | 271.796% |
| Novavax, Inc. | -487.39 Million USD | 167.023% |
| Aptorum Group Limited | -9.59 Million USD | 3503.095% |
| Ardelyx, Inc. | -55.35 Million USD | 690.134% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 285.951% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 11971.834% |
| Vaxcyte, Inc. | -464.88 Million USD | 170.267% |
| Precigen, Inc. | -89.22 Million USD | 466.107% |
| Pharming Group N.V. | 9.87 Million USD | -3207.31% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 305.385% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 1535.124% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 2023.697% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 239.9% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 1917.475% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 1454.779% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 1454.779% |
| Bicycle Therapeutics plc | -183.4 Million USD | 278.115% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 473.641% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 1227.863% |
| Acelyrin, Inc. | -381.52 Million USD | 185.62% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -61651.04% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 1078.443% |
| Senti Biosciences, Inc. | -61.33 Million USD | 632.58% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 390.874% |
| AbCellera Biologics Inc. | -192.15 Million USD | 269.997% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 1157.025% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 297.474% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 101864.174% |
| Chimerix, Inc. | -92.97 Million USD | 451.349% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 1106.573% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 1720.433% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 835.12% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 797.074% |
| Elevation Oncology, Inc. | -41.46 Million USD | 887.766% |
| Alkermes plc | 495.04 Million USD | 34.014% |
| Fortress Biotech, Inc. | -133.64 Million USD | 344.43% |
| Fortress Biotech, Inc. | -133.64 Million USD | 344.43% |
| Agenus Inc. | -145.92 Million USD | 323.858% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 522.356% |
| Dyadic International, Inc. | -8.22 Million USD | 4069.3% |
| ImmuCell Corporation | -2.5 Million USD | 13145.246% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 112355.326% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 350.468% |
| Lantern Pharma Inc. | -15.78 Million USD | 2169.231% |
| Immix Biopharma, Inc. | -16.13 Million USD | 2124.481% |
| Incyte Corporation | 919.42 Million USD | 64.471% |
| IO Biotech, Inc. | -91.22 Million USD | 458.073% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 559.933% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 1740.501% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 669.338% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 307.808% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 3990.698% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 536.628% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 185.971% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 160.501% |
| NextCure, Inc. | -59.03 Million USD | 653.3% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 3377.117% |
| Onconetix, Inc. | -36.7 Million USD | 989.927% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -14515.794% |
| Opthea Limited | -200.01 Million USD | 263.316% |
| PDS Biotechnology Corporation | -40.08 Million USD | 914.926% |
| PureTech Health plc | -11.62 Million USD | 2909.521% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 516.168% |
| Seer, Inc. | -97.88 Million USD | 433.721% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 2535340.891% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 1516.701% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 5440.645% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 1216.491% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 655.644% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 1476.292% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 367.531% |
| ChromaDex Corporation | -3.89 Million USD | 8488.88% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 4845.25% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 390.279% |
| CRISPR Therapeutics AG | -202.7 Million USD | 261.155% |
| Precision BioSciences, Inc. | -32.04 Million USD | 1119.484% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 289.668% |
| Innoviva, Inc. | 248.96 Million USD | -31.211% |
| Summit Therapeutics Inc. | 1 Million USD | -32533.666% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 625.207% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 599.752% |
| ESSA Pharma Inc. | -26.45 Million USD | 1334.773% |
| GlycoMimetics, Inc. | -39.12 Million USD | 934.986% |
| GT Biopharma, Inc. | 5.97 Million USD | -5363.506% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 258.043% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -276.288% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 737.777% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 3403.997% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 238.053% |
| Aptose Biosciences Inc. | -52.26 Million USD | 724.977% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 403.186% |
| Soligenix, Inc. | -7.85 Million USD | 4259.802% |
| Century Therapeutics, Inc. | -121.2 Million USD | 369.506% |
| Kura Oncology, Inc. | -164.95 Million USD | 298.032% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 507.829% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 3338.777% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 34207.727% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 7680.947% |
| Autolus Therapeutics plc | -156.77 Million USD | 308.371% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 485.866% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 573.418% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 1738.723% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 272.588% |
| GRI Bio, Inc. | -10.89 Million USD | 3097.458% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 7333.915% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 366.651% |
| IGM Biosciences, Inc. | -253.35 Million USD | 228.933% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 414.728% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 956.636% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 2230.748% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 2174.941% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 674.656% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 404.999% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 222.807% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 268.436% |
| Verastem, Inc. | -83.16 Million USD | 492.784% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 745.936% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 306.451% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 386.323% |
| Histogen Inc. | -10.5 Million USD | 3210.188% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 2387.603% |
| Surrozen, Inc. | -41.13 Million USD | 894.201% |
| Organovo Holdings, Inc. | -14.8 Million USD | 2306.288% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -10185837.013% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 656.371% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 736.844% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 1616.612% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 4017.76% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 296.706% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 763.161% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 1451.746% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 2269.792% |
| Apollomics, Inc. | -171.74 Million USD | 290.2% |
| Amarin Corporation plc | -50.9 Million USD | 741.755% |
| Mesoblast Limited | -61.33 Million USD | 632.623% |
| Turnstone Biologics Corp. | -56.23 Million USD | 680.899% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 328.115% |
| Synaptogenix, Inc. | -8.3 Million USD | 4032.142% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 2229.624% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 618.126% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 6917.6% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -76038.3% |
| Exelixis, Inc. | 196.6 Million USD | -66.154% |
| Better Therapeutics, Inc. | -38.26 Million USD | 953.753% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 331.006% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 165.964% |
| NLS Pharmaceutics AG | -11.79 Million USD | 2869.35% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -132036.674% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 1207.107% |
| Gritstone bio, Inc. | -126.86 Million USD | 357.493% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 602.674% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 8266.685% |
| Avid Bioservices, Inc. | -11.48 Million USD | 2945.249% |
| Insmed Incorporated | -654.73 Million USD | 149.892% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 14620.169% |
| MediWound Ltd. | -4.89 Million USD | 6776.129% |
| OmniAb, Inc. | -49.73 Million USD | 756.86% |
| Alector, Inc. | -142.89 Million USD | 328.608% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 482.357% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 726.415% |
| Zai Lab Limited | -366.57 Million USD | 189.113% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 212.396% |
| Aura Biosciences, Inc. | -83.69 Million USD | 490.297% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 245.023% |
| Immunic, Inc. | -99.11 Million USD | 429.59% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 348.092% |
| Veracyte, Inc. | -49.4 Million USD | 761.141% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 4724.38% |
| FibroGen, Inc. | -261.4 Million USD | 224.964% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 3032.08% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 4765.729% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 1845.287% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 77.463% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 1384.962% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -718.91% |
| TG Therapeutics, Inc. | 26.1 Million USD | -1151.582% |
| Galecto, Inc. | -37.51 Million USD | 970.66% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 953.686% |
| Fortrea Holdings Inc. | 167.3 Million USD | -95.256% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 343.27% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 1253.838% |
| XBiotech Inc. | -35.76 Million USD | 1013.334% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 602.674% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 600.633% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 412.731% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 1372.449% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 899.332% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 163.251% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 683.108% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 582896.025% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 380.795% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 1573.476% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 238.968% |
| NexImmune, Inc. | -28.16 Million USD | 1259.716% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 6011.866% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 2870.145% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 92.981% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 1386.48% |
| Scopus BioPharma Inc. | -11.71 Million USD | 2888.857% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 359.574% |
| Ainos, Inc. | -8.77 Million USD | 3823.462% |
| Pluri Inc. | -20.22 Million USD | 1715.145% |
| Prothena Corporation plc | -190.1 Million USD | 271.83% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 354.811% |
| Celularity Inc. | -183.94 Million USD | 277.586% |
| Rallybio Corporation | -72.37 Million USD | 551.36% |
| Cue Biopharma, Inc. | -46.05 Million USD | 809.335% |
| MeiraGTx Holdings plc | -57.05 Million USD | 672.571% |
| Omeros Corporation | -163.61 Million USD | 299.66% |
| Humacyte, Inc. | -96.45 Million USD | 438.658% |
| Immunocore Holdings plc | -59.64 Million USD | 647.642% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 1786.264% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 1440.706% |
| Blueprint Medicines Corporation | -474.61 Million USD | 168.827% |
| CalciMedica, Inc. | -34.18 Million USD | 1055.462% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 546.054% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 360.295% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 293.922% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 229.428% |
| Pulmatrix, Inc. | -12.64 Million USD | 2683.133% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 1090.909% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 469.248% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 164.518% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 422.742% |
| Cytokinetics, Incorporated | -456.68 Million USD | 171.529% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 1078.824% |
| Nutriband Inc. | -5.12 Million USD | 6477.923% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 854.906% |
| Vor Biopharma Inc. | -114.37 Million USD | 385.617% |
| Roivant Sciences Ltd. | -996.51 Million USD | 132.781% |
| Evogene Ltd. | -23.2 Million USD | 1507.787% |
| ProKidney Corp. | -147.66 Million USD | 321.213% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 606.18% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 213397.508% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 157.769% |
| CorMedix Inc. | -48.88 Million USD | 768.2% |
| BioLineRx Ltd. | -57.06 Million USD | 672.48% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 392.295% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 161814.356% |
| Atai Life Sciences N.V. | -36.31 Million USD | 999.625% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 510.809% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 501.735% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 218.57% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 1162.664% |
| MediciNova, Inc. | -9.87 Million USD | 3406.316% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 359.378% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 21447.718% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1324.89% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 245.189% |
| Biomea Fusion, Inc. | -124.62 Million USD | 362.127% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 198.887% |
| Mereo BioPharma Group plc | -26.05 Million USD | 1353.696% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 271.622% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 242.063% |
| Absci Corporation | -95.45 Million USD | 442.21% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 1187.97% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 404.956% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 239.913% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 1529.285% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 257.173% |
| Allakos Inc. | -189.91 Million USD | 272.005% |
| Imunon, Inc. | -19.87 Million USD | 1743.316% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 401.094% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -201.561% |
| BioAtla, Inc. | -122.24 Million USD | 367.229% |
| NLS Pharmaceutics AG | -11.79 Million USD | 2869.35% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 2172.603% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 208.781% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 888.146% |
| XOMA Corporation | -39.36 Million USD | 929.894% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 429.118% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 377.657% |
| aTyr Pharma, Inc. | -52.17 Million USD | 726.055% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 489.743% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 319.781% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 239.263% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 2492.61% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 4161.811% |
| Akari Therapeutics, Plc | -16.8 Million USD | 2044.191% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -173006.843% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 27.721% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 5213.197% |
| UroGen Pharma Ltd. | -63.83 Million USD | 611.762% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 580.988% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 4597.624% |
| Orgenesis Inc. | -60.71 Million USD | 638.0% |
| Entera Bio Ltd. | -8.8 Million USD | 3810.393% |
| GH Research PLC | -41.15 Million USD | 893.777% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 1380.078% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 497.241% |
| Xencor, Inc. | -125.87 Million USD | 359.516% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 22998.892% |
| Replimune Group, Inc. | -230.19 Million USD | 241.905% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 1720.544% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 3085.405% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 5213.197% |
| Portage Biotech Inc. | -18.19 Million USD | 1894.95% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 21447.718% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 412.345% |
| OncoCyte Corporation | -23.12 Million USD | 1512.719% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 2990.73% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 2951.249% |
| Purple Biotech Ltd. | -22.22 Million USD | 1569.8% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 5196.147% |
| scPharmaceuticals Inc. | -46.06 Million USD | 809.197% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 1934.188% |
| HilleVax, Inc. | -132.46 Million USD | 346.601% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 3172.162% |
| Tharimmune, Inc. | -9.3 Million USD | 3611.528% |
| Genprex, Inc. | -31.06 Million USD | 1151.697% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 274.196% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 1141.854% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 42856.937% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -216370.736% |
| OKYO Pharma Limited | -15.74 Thousand USD | 2074694.799% |
| Savara Inc. | -59.13 Million USD | 652.421% |
| Curis, Inc. | -45.13 Million USD | 823.682% |
| Daré Bioscience, Inc. | -30.7 Million USD | 1163.996% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 2250.351% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 4659.149% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 1321.901% |
| BeiGene, Ltd. | -1.12 Billion USD | 129.047% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 2103.92% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 175.865% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 461.593% |
| Erasca, Inc. | -121.31 Million USD | 369.28% |
| bluebird bio, Inc. | -167.16 Million USD | 295.418% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 7361.185% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -5.279% |
| DBV Technologies S.A. | -85.98 Million USD | 479.92% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 7361.185% |
| Moderna, Inc. | -3.28 Billion USD | 109.95% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 866.653% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 5883.693% |
| Molecular Templates, Inc. | 1.43 Million USD | -22743.566% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 645.785% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 200.128% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 338.285% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 789.657% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 334.952% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 258.682% |
| MacroGenics, Inc. | 2.01 Million USD | -16095.488% |
| RenovoRx, Inc. | -11.39 Million USD | 2967.981% |
| Adicet Bio, Inc. | -136.53 Million USD | 339.252% |
| Prime Medicine, Inc. | -193.75 Million USD | 268.592% |
| Aditxt, Inc. | -25.45 Million USD | 1383.147% |
| Adagene Inc. | -14.95 Million USD | 2284.922% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 4568.654% |
| Quantum-Si incorporated | -91.8 Million USD | 455.827% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 54.147% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | -158.324% |
| SciSparc Ltd. | -5.28 Million USD | 6284.457% |
| Vericel Corporation | 2.86 Million USD | -11305.831% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 343204.571% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 1605.954% |
| Generation Bio Co. | -133.3 Million USD | 345.059% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 493.428% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 479.739% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 243.63% |
| Invivyd, Inc. | -196.61 Million USD | 266.143% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 187.307% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 3622.05% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -1103.001% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 3276.111% |
| 2seventy bio, Inc. | -206.41 Million USD | 258.253% |
| ADMA Biologics, Inc. | 5.12 Million USD | -6280.137% |
| Clene Inc. | -43.24 Million USD | 855.447% |
| Capricor Therapeutics, Inc. | -23 Million USD | 1519.72% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 773.852% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1324.89% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 209.045% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 989.379% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -1285.751% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -6552.669% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 1105.674% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 306.221% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 147.736% |
| Evaxion Biotech A/S | -21.4 Million USD | 1626.249% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 591.851% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 250.073% |
| Trevena, Inc. | -35.28 Million USD | 1025.706% |
| Surrozen, Inc. | -41.13 Million USD | 894.201% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 510.422% |
| Cingulate Inc. | -22.95 Million USD | 1523.242% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 4478.274% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 976.171% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 4070.925% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 419.425% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 581.612% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 659.623% |
| Clearmind Medicine Inc. | -8.71 Million USD | 3850.151% |
| Kronos Bio, Inc. | -121.83 Million USD | 368.13% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 539.406% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 13480.074% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 423.984% |
| Statera Biopharma, Inc. | 38.93 Million USD | -738.997% |
| ImmunityBio, Inc. | -436.18 Million USD | 174.891% |
| Korro Bio, Inc. | -80.9 Million USD | 503.766% |
| Kineta, Inc. | -15.71 Million USD | 2178.802% |
| BioVie Inc. | -31.95 Million USD | 1122.413% |
| Codexis, Inc. | -49.28 Million USD | 762.831% |
| Celularity Inc. | -183.94 Million USD | 277.586% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 247.471% |
| Celcuity Inc. | -58.3 Million USD | 660.218% |
| Virax Biolabs Group Limited | -6.6 Million USD | 5042.592% |
| Cibus, Inc. | -314.58 Million USD | 203.839% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 1068.378% |
| IN8bio, Inc. | -28.5 Million USD | 1246.025% |
| Kodiak Sciences Inc. | -259.02 Million USD | 226.114% |
| Annexon, Inc. | -141.57 Million USD | 330.735% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 390.112% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 608.853% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 1268.532% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 242.021% |
| Eyenovia, Inc. | -24.1 Million USD | 1455.109% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -629.419% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 100921.914% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 542.609% |
| Arcellx, Inc. | -64.14 Million USD | 609.257% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 825.692% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 364.556% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 1157.778% |
| Moolec Science SA | -52.07 Million USD | 727.287% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 732.994% |
| Geron Corporation | -174.78 Million USD | 286.897% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 908.232% |
| Royalty Pharma plc | 1.88 Billion USD | 82.691% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 373.146% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 3603.369% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 1674.981% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 296.69% |
| Humacyte, Inc. | -96.45 Million USD | 438.658% |
| Structure Therapeutics Inc. | -102.45 Million USD | 418.823% |
| 89bio, Inc. | -134.46 Million USD | 342.939% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 514.153% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -7961.772% |
| Genelux Corporation | -24.16 Million USD | 1451.802% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 1066.459% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 299.838% |
| Notable Labs, Ltd. | -14.4 Million USD | 2368.493% |
| Liquidia Corporation | -70.05 Million USD | 566.322% |
| Mustang Bio, Inc. | -48.06 Million USD | 779.656% |
| Immunovant, Inc. | -269.97 Million USD | 220.996% |
| Quantum-Si incorporated | -91.8 Million USD | 455.827% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 560.179% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 1791.853% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 420.22% |
| Acasti Pharma Inc. | -11.3 Million USD | 2990.567% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 1567.934% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 2230.748% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 255.175% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 7749.573% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 2157.072% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 1235.193% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 982.158% |
| PepGen Inc. | -83.58 Million USD | 490.829% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 1207.182% |
| United Therapeutics Corporation | 1.38 Billion USD | 76.445% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 1526.663% |
| Solid Biosciences Inc. | -93.43 Million USD | 449.619% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 6945.789% |
| Immuneering Corporation | -58.06 Million USD | 662.622% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -10185837.013% |
| Silo Pharma, Inc. | -3.62 Million USD | 9108.376% |
| Belite Bio, Inc | -31.52 Million USD | 1136.072% |
| XOMA Corporation | -39.36 Million USD | 929.894% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 584.325% |
| Bionomics Limited | -9.83 Million USD | 3420.76% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 488.954% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 1043.949% |
| uniQure N.V. | -253.1 Million USD | 229.065% |
| Cassava Sciences, Inc. | -95.68 Million USD | 441.387% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 4568.654% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 352.242% |
| Forte Biosciences, Inc. | -32.47 Million USD | 1105.829% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 4157.687% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 1257.599% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 100921.914% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 3032.08% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 2154.355% |
| Altimmune, Inc. | -87.93 Million USD | 471.482% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 454.764% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 1043.949% |
| Compugen Ltd. | -12.51 Million USD | 2709.963% |
| Peak Bio, Inc. | -1356.23 USD | 24086206.339% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 772.174% |
| Benitec Biopharma Inc. | -22.49 Million USD | 1552.481% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 234.816% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 1244.459% |
| Zura Bio Limited | -60.56 Million USD | 639.377% |
| PolyPid Ltd. | -20.26 Million USD | 1712.116% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 2192.25% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 1244.459% |
| Instil Bio, Inc. | -146.12 Million USD | 323.555% |
| argenx SE | -216.02 Million USD | 251.217% |
| Immunome, Inc. | -28.27 Million USD | 1255.47% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 773.907% |
| Verona Pharma plc | -52.46 Million USD | 722.6% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 444.683% |
| Shattuck Labs, Inc. | -87.61 Million USD | 472.839% |
| CervoMed Inc. | -2.17 Million USD | 15140.605% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 367.222% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 2673.568% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 778.09% |
| Moolec Science SA | -52.07 Million USD | 727.287% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 2005.854% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 350.526% |
| AnaptysBio, Inc. | -143.16 Million USD | 328.174% |
| Design Therapeutics, Inc. | -66.32 Million USD | 592.519% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 503.352% |
| NeurAxis, Inc. | -6.66 Million USD | 5001.542% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 965.332% |
| Lumos Pharma, Inc. | -36.57 Million USD | 993.254% |
| Achilles Therapeutics plc | -70.44 Million USD | 563.733% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 444.683% |
| 180 Life Sciences Corp. | -22.13 Million USD | 1575.841% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -5503.863% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 13480.074% |
| Nutriband Inc. | -5.12 Million USD | 6477.923% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 397.648% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 689.304% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 746.218% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 600.426% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 703.702% |
| Palisade Bio, Inc. | -12.28 Million USD | 2759.906% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 819.903% |
| Beam Therapeutics Inc. | -156.47 Million USD | 308.766% |
| Neurogene Inc. | -52.28 Million USD | 724.762% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 339.331% |
| AEON Biopharma, Inc. | -48.36 Million USD | 775.468% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 451.183% |
| Sesen Bio, Inc. | -50.84 Million USD | 742.531% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 498.7% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 2745.04% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 176.425% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 410.525% |
| Athira Pharma, Inc. | -116.7 Million USD | 379.91% |
| Vaccinex, Inc. | -19.74 Million USD | 1754.157% |
| HCW Biologics Inc. | -23.57 Million USD | 1485.571% |
| XOMA Corporation | -39.36 Million USD | 929.894% |
| Nektar Therapeutics | -243.1 Million USD | 234.37% |
| Arvinas, Inc. | -394.8 Million USD | 182.741% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -173006.843% |
| Merus N.V. | -149.2 Million USD | 318.933% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 449.41% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 1144.987% |
| Rezolute, Inc. | -68.42 Million USD | 577.417% |
| Clene Inc. | -43.24 Million USD | 855.447% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 2218.136% |
| BeyondSpring Inc. | -21.54 Million USD | 1616.541% |
| Synlogic, Inc. | -55.16 Million USD | 692.199% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 2803.493% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 3169.564% |
| Peak Bio, Inc. | -1356.23 USD | 24086206.339% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 1106.201% |
| Krystal Biotech, Inc. | 17.9 Million USD | -1724.525% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 375.844% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 195.698% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 7191.454% |
| MannKind Corporation | 15.12 Million USD | -2059.184% |
| Ikena Oncology, Inc. | -74.39 Million USD | 539.081% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 2694.005% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -1507.04% |
| Gossamer Bio, Inc. | -172.15 Million USD | 289.753% |
| CohBar, Inc. | -12.06 Million USD | 2807.356% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 1380.579% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 1187.97% |
| Legend Biotech Corporation | -477.87 Million USD | 168.358% |
| Mural Oncology plc | -192.72 Million USD | 269.501% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 386.411% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 2123.274% |
| Disc Medicine, Inc. | -91.02 Million USD | 458.872% |
| Champions Oncology, Inc. | -5.05 Million USD | 6563.455% |
| REGENXBIO Inc. | -239.46 Million USD | 236.414% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 3147.745% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 685.88% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 942.604% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 389.579% |
| Vaxart, Inc. | -74.72 Million USD | 537.165% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 1027.801% |
| Cellectis S.A. | -98.09 Million USD | 433.007% |
| Longeveron Inc. | -20.06 Million USD | 1728.43% |
| Repare Therapeutics Inc. | -114.27 Million USD | 385.862% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 174.377% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 536.645% |
| Revolution Medicines, Inc. | -430.58 Million USD | 175.865% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 5294.196% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 1160.973% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 537.945% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -6562.513% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 3079.143% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 92.907% |
| Denali Therapeutics Inc. | -179.97 Million USD | 281.507% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 343204.571% |
| Veru Inc. | -89.97 Million USD | 463.057% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 1315.355% |
| Cingulate Inc. | -22.95 Million USD | 1523.242% |
| Passage Bio, Inc. | -98.34 Million USD | 432.174% |
| Context Therapeutics Inc. | -25.06 Million USD | 1403.494% |
| Exicure, Inc. | -15.53 Million USD | 2202.214% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 258.525% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 983.446% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 5578.537% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 293.907% |
| Nuvalent, Inc. | -149.49 Million USD | 318.515% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 4116.802% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 480.309% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 1182.454% |
| OmniAb, Inc. | -49.73 Million USD | 756.86% |
| Anew Medical, Inc. | -1.3 Million USD | 25211.697% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 2742.049% |
| Lipocine Inc. | -16.32 Million USD | 2101.285% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 589.97% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 539.636% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 956.636% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 937.297% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 1572.583% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 159.93% |
| Ocugen, Inc. | -64.82 Million USD | 603.9% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 452.882% |
| Q32 Bio Inc. | -86.5 Million USD | 477.636% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 2029.834% |
| Alumis Inc. Common Stock | -156.89 Million USD | 308.211% |
| Equillium, Inc. | -12.13 Million USD | 2791.242% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 658.666% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 4233.223% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 1831.952% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 799.612% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 407.173% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 1926.301% |
| Dominari Holdings Inc. | -22.44 Million USD | 1555.717% |
| Edesa Biotech, Inc. | -8.19 Million USD | 4088.49% |
| vTv Therapeutics Inc. | -25.41 Million USD | 1385.467% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 184.878% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | -50.961% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 349.156% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 972.707% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 316.189% |
| Nkarta, Inc. | -120.48 Million USD | 371.132% |
| BioCardia, Inc. | -11.56 Million USD | 2925.804% |
| Iterum Therapeutics plc | -34.58 Million USD | 1044.659% |